Needham analyst Ami Fadia initiated coverage of Revolution Medicines with a Buy rating and $31 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RVMD:
- Revolution Medicines price target raised to $32 from $30 at H.C. Wainwright
- Revolution to regain rights to RMC-4630 following Sanofi deal termination
- Sanofi terminates SHP2 Inhibitor development pact with Revolution Medicines
- Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
- Revolution Medicines to Participate in Upcoming Investor Conferences